Source: Business Wire

Press Release: Valneva : Lyme Disease - Pipeline Review, H1 2016 - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets ( has announced the addition of the "Lyme Disease - Pipeline Review, H1 2016" report to their offering. The report provides comprehensive information on the therapeutics under development for Lyme Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmaco

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue


Thomas Lingelbach's photo - President & CEO of Valneva

President & CEO

Thomas Lingelbach

CEO Approval Rating


Valneva is a biotechnology company that develops and commercializes vaccines for the treatment of infectious diseases.

Read more